GSK vs. PFE
Compare and contrast key facts about GlaxoSmithKline plc (GSK) and Pfizer Inc. (PFE).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GSK or PFE.
Key characteristics
GSK | PFE | |
---|---|---|
YTD Return | 18.11% | -2.34% |
1Y Return | 22.43% | -24.25% |
3Y Return (Ann) | 8.78% | -7.83% |
5Y Return (Ann) | 5.67% | -3.03% |
10Y Return (Ann) | 2.50% | 3.45% |
Sharpe Ratio | 1.33 | -1.03 |
Daily Std Dev | 18.07% | 24.67% |
Max Drawdown | -55.72% | -69.72% |
Current Drawdown | -1.78% | -50.45% |
Fundamentals
GSK | PFE | |
---|---|---|
Market Cap | $83.99B | $143.83B |
EPS | $2.99 | $0.37 |
PE Ratio | 13.75 | 68.65 |
PEG Ratio | 1.09 | 0.26 |
Revenue (TTM) | $30.33B | $58.50B |
Gross Profit (TTM) | $19.92B | $66.23B |
EBITDA (TTM) | $10.30B | $11.52B |
Correlation
The correlation between GSK and PFE is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
GSK vs. PFE - Performance Comparison
In the year-to-date period, GSK achieves a 18.11% return, which is significantly higher than PFE's -2.34% return. Over the past 10 years, GSK has underperformed PFE with an annualized return of 2.50%, while PFE has yielded a comparatively higher 3.45% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GSK vs. PFE - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
GSK vs. PFE - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 3.35%, less than PFE's 5.96% yield.
TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
GlaxoSmithKline plc | 3.35% | 3.75% | 4.72% | 4.93% | 5.53% | 4.35% | 5.53% | 5.80% | 6.89% | 5.94% | 6.18% | 4.49% |
Pfizer Inc. | 5.96% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.54% | 3.70% | 3.47% | 3.34% | 3.14% |
Drawdowns
GSK vs. PFE - Drawdown Comparison
The maximum GSK drawdown since its inception was -55.72%, smaller than the maximum PFE drawdown of -69.72%. Use the drawdown chart below to compare losses from any high point for GSK and PFE. For additional features, visit the drawdowns tool.
Volatility
GSK vs. PFE - Volatility Comparison
The current volatility for GlaxoSmithKline plc (GSK) is 5.49%, while Pfizer Inc. (PFE) has a volatility of 8.88%. This indicates that GSK experiences smaller price fluctuations and is considered to be less risky than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
GSK vs. PFE - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities